AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Other COPD medication
- First Posted Date
- 2017-09-21
- Last Posted Date
- 2023-01-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 26839
- Registration Number
- NCT03290287
- Locations
- 🇬🇧
Clinical Practice Research Datalink, London, United Kingdom
To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
Phase 3
Completed
- Conditions
- Somatic BRCA1/2 MutationsHER2-ve Metastatic Breast CancerGermline BRCA1/2 Mutations
- Interventions
- First Posted Date
- 2017-09-19
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 256
- Registration Number
- NCT03286842
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)
Phase 1
Completed
- Conditions
- Hyperkalemia
- Interventions
- Drug: Sodium Zirconium Cyclosilicate (ZS)
- First Posted Date
- 2017-09-14
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22
- Registration Number
- NCT03283267
- Locations
- 🇭🇰
Research Site, Hong Kong, Hong Kong
Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT03276078
- Locations
- 🇨🇳
Research Site, Changchun, China
A Phase I, Open-Label, Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Participants
- First Posted Date
- 2017-09-08
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 20
- Registration Number
- NCT03276052
- Locations
- 🇨🇳
Research Site, Chengdu, China
To Assess the Pharmacokinetics, Safety and Tolerability of Abediterol Administered Once Daily for 9 Days, in Patients With Asthma on Inhaled Corticosteroids
- First Posted Date
- 2017-09-06
- Last Posted Date
- 2017-11-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT03273127
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Single Ascending Dose Study of MEDI1341 in Healthy Volunteers
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT03272165
- Locations
- 🇺🇸
Research Site, Madison, Wisconsin, United States
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
Phase 1
Completed
- Conditions
- High Risk Myelodysplastic SyndromeT-cell Non-Hodgkin LymphomaRelapsed or Refractory Haematological Malignancies IncludingAcute Myeloid LeukemiaAcute Lymphocytic LeukemiaSmall Lymphocytic LymphomaChronic Myelomonocytic LeukemiaRichter's SyndromeB-cell Non-Hodgkin LymphomaChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2017-08-28
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 44
- Registration Number
- NCT03263637
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
- Conditions
- NF type1 With Inoperable Plexiform Neurofibromas
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT03259633
- Locations
- 🇺🇸
Research Site, New Orleans, Louisiana, United States
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT03258515
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath